ArticleClinical ophthalmology (Auckland, N.Z.)2025

Biosimilar Versus Innovator Ranibizumab in Myopic CNVM: Comparative Real-World Outcomes- The BRIM Study.

Debdulal Chakraborty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.